Latest news
Recursion Pharmaceuticals (RXRX) Reported Q2 Revenue Pressure, Is The Valuation Gap Too Wide? - simplywall.stsimplywall.st · Sat, 08 Aug 2026 05:45:45 GMTBofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Maintains Target Price $6 - MoomooMoomoo · Fri, 07 Aug 2026 14:41:30 GMTRecursion Pharmaceuticals (RXRX) Director Blake Borgeson Sells 3 - GuruFocusGuruFocus · Fri, 07 Aug 2026 07:50:49 GMTRecursion Pharmaceuticals (RXRX) director sells 30,000 shares in 10b5-1 plan - Stock TitanStock Titan · Thu, 06 Aug 2026 21:10:07 GMTRXRX Aug 2026 6.000 put (RXRX260821P00006000) interactive stock chart - Yahoo Finance UKYahoo Finance UK · Thu, 06 Aug 2026 18:14:39 GMTRXRX Q2 Earnings Miss Estimates, Revenues Fall Y/Y, Stock Down - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 14:58:00 GMTBank of New York Mellon Corp Boosts Stake in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeatMarketBeat · Thu, 06 Aug 2026 07:35:21 GMTRXRX SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocusGuruFocus · Thu, 06 Aug 2026 06:23:09 GMT